The final TLR3 agonist evaluated in the identified trials for both a rabies (NCT05667974) and COVID‐19 (NCT05463419) vaccine is PIKA, a stabilized chemical analog of dsRNA developed by YS Biopharma. The gene discussed is TLR3; the disease is COVID-19.